United Therapeutics Settles Liquidia Litigation for $330.4M, Forces Yutrepia PH-ILD Label Removal
UTHR sits 33% above its 52-week low of $409.07.
Summary
United Therapeutics settled all patent and antitrust litigation with Liquidia. Liquidia pays $330.4M and must remove the PH-ILD indication from Yutrepia, eliminating a direct competitor to Tyvaso.
Key Events · Legal and Risk Events · UTHR
-
Settlement Agreement Executed
United Therapeutics and Liquidia signed a settlement on October 13, 2026 resolving all patent infringement and trade secrets litigation between the parties.
-
Liquidia to Pay $330.4M
Liquidia will pay $185M within 30 business days for past Yutrepia PH-ILD sales, plus $145.4M in two installments of $72.7M each due February 1, 2027 and April 30, 2027 for ongoing sales.
-
Yutrepia PH-ILD Indication Removed
Liquidia must immediately file with FDA to remove the PH-ILD indication from Yutrepia's label and cease all marketing, promotion, and detailing of Yutrepia for PH-ILD, protecting Tyvaso's market position.
-
RareGen/Sandoz Antitrust Case Settled
UT will pay $10M to settle the RareGen/Sandoz antitrust litigation, which had produced a $61.6M damages award that the Third Circuit vacated on October 7, 2026.
Analysis · UTHR · Life Sciences
United Therapeutics locked in a comprehensive settlement with Liquidia that eliminates a major competitive threat to its Tyvaso franchise. Liquidia will pay $330.4 million in damages and must immediately stop marketing Yutrepia for PH-ILD, the indication that directly competes with Tyvaso. The settlement also resolves the long-running RareGen/Sandoz antitrust case for a $10 million payment, removing a legal overhang that had produced a $61.6 million damages award against UT — an award the Third Circuit vacated on October 7. The net effect is a cash inflow of roughly $320 million and, more importantly, the removal of a competing PH-ILD product from the market, protecting a key revenue stream.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 36.5% of the 953 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UTHR was trading at $542.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.3B. The 52-week trading range was $409.07 to $609.35. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.